News archive
Showing 796 results
December 2020
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation Xolair is now FDA-approved across three diseases and in…
November 2020
-
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs ELARA results for Kymriah® in relapsed or… -
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
-
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult… -
Story Medicines
Novartis looks to the brightest academic minds to reimagine metastatic breast cancer treatment
More than 16 teams from US universities participated in the first US oncology data science hackathon to tackle current challenges in metastatic breast cancer treatments.
-
Media Release
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media Release
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11 ULTIMATE is the first ever Phase IIIb…
October 2020
-
Statement
New policy related to the 340B program
-
Media Release
Novartis STEP Program™ awards nearly $375,000 to patient advocacy organizations for their innovative solutions in biomarker testing; now accepting proposals for caregiving in cancer and certain blood disorders
The STEP (Solutions to Empower Patients) ProgramTM supports nonprofit organizations that deliver creative solutions to address barriers to care Five patient advocacy organizations were provided… -
Media Release
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine